1-2 of 2
Kimio Yonesaka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer

Free
Satomi Watanabe, Takeshi Yoshida, Hisato Kawakami, Naoki Takegawa, Junko Tanizaki, Hidetoshi Hayashi, Masayuki Takeda, Kimio Yonesaka, Junji Tsurutani, Kazuhiko Nakagawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (11): 2563–2571.
https://doi.org/10.1158/1535-7163.MCT-17-0351
Published: 01 November 2017
View article titled, T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer
Open the PDF for T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer in another window
Journal Articles

Abstract A177: Cetuximab resistance associated with dimerization‐independence of oncogenic EGFR mutants

Free
Jeonghee Cho, Liang Chen, Naveen Sangji, Jinyan Du, Takafumi Okabe, Kimio Yonesaka, Joshua M. Francis, Richard J. Flavin, Soyoung Yu, Heidi E. Greulich, Bruce E. Johnson, Michael J. Eck, Pasi A. Jänne, Kwok‐Kin Wong, Matthew Meyerson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A177.
https://doi.org/10.1158/1535-7163.TARG-09-A177
Published: 10 December 2009
View article titled, Abstract A177: Cetuximab resistance associated with dimerization‐independence of oncogenic EGFR mutants